首页 | 本学科首页   官方微博 | 高级检索  
检索        

肺岩宁方调控MALAT1抑制A549肺癌细胞侵袭的机制研究
引用本文:康小红,王颖,崔艳慧,寇卫政,曹飞,苗战会,徐振晔,邓海滨,龚亚斌.肺岩宁方调控MALAT1抑制A549肺癌细胞侵袭的机制研究[J].上海中医药杂志,2019,53(3):77-82.
作者姓名:康小红  王颖  崔艳慧  寇卫政  曹飞  苗战会  徐振晔  邓海滨  龚亚斌
作者单位:新乡医学院第一附属医院肿瘤科;上海中医药大学附属龙华医院肿瘤科;上海中医药大学附属岳阳中西医结合医院肿瘤科
基金项目:国家自然科学基金项目(81503414、81874392);上海市教委科研创新计划项目(2017-01-07-00-10-E00064)
摘    要:目的探讨肺岩宁方调控肺腺癌转移相关转录本1(MALAT1)抑制A549肺癌细胞侵袭的机制。方法向A549细胞转染LV-vector、LV-over/MALAT1慢病毒载体,应用肺岩宁方(0~500μg/ml)干预细胞,应用实时定量聚合酶链式反应(qRT-PCR)法检测MALAT1表达情况;应用四甲基偶氮唑盐(MTT)比色法检测肺岩宁方对肿瘤细胞增殖的影响;细胞侵袭实验检测肿瘤侵袭能力;Western blot法检测Wnt/β-catenin/EMT信号通路相关蛋白的表达。结果细胞侵袭实验结果显示,过表达MALAT1可增强A549细胞的侵袭能力,与正常对照组和慢病毒载体组相比,差异有统计学意义(P0.01);与正常对照组相比,肺岩宁方可抑制A549细胞侵袭,差异有统计学意义(P0.01),但过表达MALAT1后可减弱肺岩宁抑制细胞侵袭的能力。MTT结果显示,肺岩宁方可抑制肺癌A549细胞增殖,且呈浓度依赖性。qRT-PCR结果显示,肺岩宁方可下调MALAT1表达。Western blot结果显示,MALAT1可下调E-cadherin蛋白,上调N-cadherin、Snail及细胞核中β-catenin的蛋白水平,肺岩宁方能上调E-cadherin蛋白,下调N-cadherin、Snail及细胞核中β-catenin的蛋白水平,但过表达MALAT1可削弱肺岩宁对这些蛋白的调控作用。结论 MALAT1过表达通过激活Wnt/β-catenin通路,加速EMT进程促进A549肺癌细胞侵袭;肺岩宁方能够通过下调MALAT1,抑制Wnt/β-catenin/EMT信号轴,从而阻止A549肺癌细胞侵袭。

关 键 词:肺癌  肺岩宁方  A549肺癌细胞  肺腺癌转移相关转录本1  上皮-间质转化  Wnt/β-catenin通路
收稿时间:2018/12/10 0:00:00

Mechanism study on Feiyanning Recipe inhibiting invasion of A549 lung cancer cells by regulating MALAT1
KANG Xiaohong,WANG Ying,CUI Yanhui,KOU Weizheng,CAO Fei,MIAO Zhanhui,XU Zhenye,DENG Haibin and GONG Yabin.Mechanism study on Feiyanning Recipe inhibiting invasion of A549 lung cancer cells by regulating MALAT1[J].Shanghai Journal of Traditional Chinese Medicine,2019,53(3):77-82.
Authors:KANG Xiaohong  WANG Ying  CUI Yanhui  KOU Weizheng  CAO Fei  MIAO Zhanhui  XU Zhenye  DENG Haibin and GONG Yabin
Institution:Department of Oncology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China,Department of Oncology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China,Department of Oncology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China,Department of Oncology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China,Department of Oncology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China,Department of Oncology, First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China,Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China,Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China and Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
Abstract:
Keywords:
本文献已被 CNKI 等数据库收录!
点击此处可从《上海中医药杂志》浏览原始摘要信息
点击此处可从《上海中医药杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号